First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
She joins Enveda from Gilead Sciences
First and only PARP inhibitor to improve invasive disease-free survival in patients
The Congress was held on June, 20-21, 2022 in Berlin, Germany
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
Subscribe To Our Newsletter & Stay Updated
